Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMC125 Roll-Over Study in HIV-1
NCT00111280Phase 2Completed
- Sponsor
- Tibotec
- Start
- Sep 2004
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of etravirine in human immunodeficiency virus infection (HIV), sponsored by Tibotec. Primary endpoint: Long-term Safety and Tolerability at 48 weeks. Started Sep 2004; status: completed.
02
Drugs
etravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00111280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111280.